The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Venglustat for treating gangliosidoses in people 2 years and over [ID6358]. For information, ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

There is a simple discount patient access scheme for trifluridine–tipiracil. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

Trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) is available on the NHS. It is a possible treatment for metastatic colorectal cancer in adults who have had 2 lines of treatment (including ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'inputs and eligible population' and 'unit costs' worksheets in the template to reflect ...

Trifluridine–tipiracil with bevacizumab is recommended, within its marketing authorisation, for treating metastatic colorectal cancer in adults who have had 2 lines of treatment (including ...

Trifluridine–tipiracil (Lonsurf, Servier Laboratories) plus bevacizumab is indicated for 'the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer ...